Allergy
Nextmune Allergy Program
The gold standard in allergy managementNextmune’s allergy programme is the gold standard and the world’s number one in terms of allergy diagnostics and treatment. Nextmune offers a complete product range, from Next+ and NextEQuine – innovative and high-quality diagnostics – to the only licensed immunotherapy in Europe – Artuvetrin® Therapy.
Next+ Serum Test
Next+ Serum Test is the leading allergy IgE serum test on the market. It is an innovative serological test that detects IgE in the serum of dogs and cats. It has all the benefits of our proprietary oligoclonal technology and it employs the new generation of CCD blockers – Next+ has the highest specificity and sensitivity in the market
NextEQuine Serum Test
NextEQuine Serum Test is the most specific horse-serum test on the market. This innovative serological test detects IgE in the serum of horses. Our proprietary monoclonal antibody 1C12, derived from a recombinant horse-specific IgE, guarantees the highest level of specificity and sensitivity.
Next+ Food Reactivity Test
Next+ Food Reactivity Test is a useful tool for determining the composition of a suitable elimination diet. It helps identify which food ingredients the patient is most likely not to be sensitive to, making it suitable for a food elimination trial.
Artuvetrin® Skin Test
Artuvetrin® Skin Test is an intradermal test that identifies which environmental allergens the patient is reactive to. By injecting small doses of allergens into the skin (and depending on the subsequent skin reaction) it is possible to determine which allergens the patient is sensitive to.
Artuvetrin® Therapy
Artuvetrin® Therapy is the only licensed immunotherapy in Europe. It treats the root cause of the allergy and reduces the symptoms. Artuvetrin Therapy® is tailored specifically to the individual patient. After determining what the dog, cat or horse is allergic to using our allergy tests, the allergy can be kept under control. Symptoms are greatly reduced and potentially eliminated. This therapy has proven efficacy (75%) and safety, and therefore can be given over long periods.